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Abstract
OBJECTIVES: The role of cytoreductive nephrectomy (CN) in the treatment
of patients harboring metastatic renal cell carcinoma (mRCC) has become
controversial since the emergence of effective targeted therapies. The aim of
our study was to compare the overall survival (OS) between CN and non-
CN groups of patients presenting with mRCC in the era of targeted drugs
and to assess these outcomes among the different Memorial Sloan-Kettering
Cancer Center (MSKCC) and The Eastern Cooperative Oncology Group (ECOG)
performance status subgroups. METHODS AND MATERIALS: A total of 351
patients with mRCC at diagnosis recruited from 18 tertiary care centers who had
been treated with systemic treatment were included in this retrospective study.
OS was assessed by the Kaplan-Meier method according to the completion of a
CN. The population was subsequently stratified according to MSKCC and ECOG
prognostic groups. RESULTS: Median OS in the entire cohort was 37.1 months.
Median OS was significantly impro...
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Abstract
Objectives: The role of cytoreductive nephrectomy (CN) in the treatment of patients harboring metastatic renal cell carcinoma (mRCC) has
become controversial since the emergence of effective targeted therapies. The aim of our study was to compare the overall survival (OS) between
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CN and non-CN groups of patients presenting with mRCC in the era of targeted drugs and to assess these outcomes among the different Memorial
Sloan-Kettering Cancer Center (MSKCC) and The Eastern Cooperative Oncology Group (ECOG) performance status subgroups.
Methods and materials: A total of 351 patients with mRCC at diagnosis recruited from 18 tertiary care centers who had been treated
with systemic treatment were included in this retrospective study. OS was assessed by the Kaplan-Meier method according to the completion
of a CN. The population was subsequently stratiﬁed according to MSKCC and ECOG prognostic groups.
Results: Median OS in the entire cohort was 37.1 months. Median OS was signiﬁcantly improved for patients who underwent CN (16.4
vs. 38.1 months, Po 0.001). However, subgroup analysis demonstrated that OS improvement after CN was only signiﬁcant among the
patients with an ECOG score of 0 to 1 (16.7 vs. 43.3 months, P ¼ 0.03) and the group of patients with good and intermediate MSKCC
score (16.8 vs. 42.4 months, P ¼ 0.02). On the contrary, this beneﬁt was not signiﬁcant for the patients with an ECOG score of 2 to 3 (8.0
vs. 12.6 months, P ¼ 0.8) or the group with poor MSKCC score (5.2 vs. 5.2, P ¼ 0.9).
Conclusions: CN improves OS in patients with mRCC. However, this effect does not seem to be signiﬁcant for the patients in ECOG
performance status groups of 2 to 3 or poor MSKCC prognostic group. r 2015 Elsevier Inc. All rights reserved.
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1. Introduction
Cytoreductive nephrectomy (CN) is still considered stand-
ard of care for patients with metastatic renal cell carcinoma
(mRCC) [1]. There are 2 prospective randomized trials that
have proven the overall survival (OS) beneﬁt of CN in patients
with mRCC in the era of immunotherapy [2,3]. In a pooled
analysis of both the trials, CN was associated with a decreased
risk of death and a mean increased OS of 6 months [4].
Since the completion of these studies, new treatments have
emerged. Targeted therapies (vascular endothelial growth
factor monoclonal antibodies, tyrosine kinase inhibitors,
and mammalian target of rapamycin inhibitors) have been
validated and proven superior to immunotherapy by several
phase 3 clinical trials [5–8]. Since then, these treatments have
become cornerstones in the therapeutic strategies for patients
with mRCC [1]. Even if these molecules have been evaluated
in patients who previously underwent nephrectomy, their
efﬁcacy has also been reported on primary tumors [9].
Consequently, interest of CN is now debated in the era of
targeted therapies. It has been reported that CN has already
declined since the approval of antiangiogenic treatments [10].
We thought to assess the effect of CN on OS for patients
with mRCC treated with systemic drugs including targeted
therapies and to analyze this effect among the different
Memorial Sloan-Kettering Cancer Center (MSKCC) and the
Eastern Cooperative Oncology Group (ECOG) performance
status prognostic subgroups.
2. Methods and materials
2.1. Data collection
The study included patients having mRCC from 18
academic centers from 1999 to 2009.
Patients received systemic drugs alone or after CN. Systemic
drugs included oral sunitinib or sorafenib, temsirolimus, inter-
feron, bevacizumab, or interleukin-2 according to ongoing
expert guidelines. The CN procedure was performed by
open access or laparoscopically. If CN was not performed,
histological conﬁrmation of RCC was performed by biopsies
from primary or metastatic lesions or both. Patient records were
retrospectively extracted from each institutional database to
obtain information regarding age, body mass index, ECOG–
performance status (ECOG-PS), American Society of Anes-
thesiologists score, MSKCC score, TNM category, tumor size,
histology, Fuhrman grade, and survival outcomes.
Tumor category was determined according to the 2002
Union Internationale Contre le Cancer revised TNM classiﬁca-
tion [11]. Malignancy on histology was reported according to
the Heidelberg classiﬁcation, and tumor grading was assessed
according to the Fuhrman grading scheme by the pathologists
of each institution [12,13]. ECOG-PS, American Society of
Anesthesiologists, and MSKCC scores were determined accord-
ing to the original criteria [14–16].
2.2. Statistical analysis
The population was subsequently stratiﬁed according to
ECOG and MSKCC prognostic groups. Clinicopathological
variables were compared by using the chi-square test or
Fischer exact test for qualitative values and the Student t
test for quantitative values. All P values were 2 sided, and a
Po 0.05 was considered signiﬁcant. OS was estimated in
different prognostic groups according to the completion of a
nephrectomy using the Kaplan-Meier method and compared
with the log-rank test. All data analysis was processed
through the SPSS 12.0 statistical software (Chicago, IL).
3. Results
3.1. Patients and tumors characteristics
A total of 351 patients with mRCC at diagnosis were
included in this retrospective study. Main patient and tumor
characteristics, especially TNM category, nuclear grade, and
histology, are described in Table 1. The patient cohort included
252 men (71.8%) and 99 women (28.2%). Median age at
diagnosis was 60.2 years [19–91] and median tumor size was
8.5 cm. ECOG-PS of 2 to 3 and poor MSKCC prognosis were
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noted in 19.4% and 10.3% of the patients, respectively. Most of
the patients (67%) presented with 1 or 2 metastatic sites at
diagnosis.
3.2. Treatment strategies
CN was performed in 298 patients (84.9%). First-line
systemic treatment was initiated with a median time of 3
months (range: 0–164) after CN and included antiangiogenic
drugs for 69.4% of patients (sunitinib, 39.0%; sorafenib, 18.5%;
temsirolimus, 7.1%; and bevacizumab, 4.8%). Details of ﬁrst-
line systemic treatment are presented in Table 2.
3.3. Comparison of CN and non-CN groups
Table 3 shows patient and disease characteristics accord-
ing to nephrectomy status. Patients who underwent neph-
rectomies were signiﬁcantly younger than patients who did
not (59.0 vs. 65.5 years respectively, Po 0.0001). Median
tumor size was higher in the CN group (9.3 vs. 7 cm,
P ¼ 0.01). Patients with systemic treatment alone (without
prior nephrectomy) had signiﬁcantly worse MSKCC and
ECOG performance status scores (P ¼ 0.05 and P ¼ 0.01,
respectively). Sex ratio, histological subtype, T category,
Fuhrman grade, and number of metastatic sites at diagnosis
were not signiﬁcantly different between both the groups.
3.4. Follow-up and survival
Considering the entire cohort, median OS was 37.1
months. Median OS was signiﬁcantly improved in patients
who underwent CN from 16.4 to 38.1 months (Po 0.001)
(Fig. 1). However, considering the ECOG score, CN was
associated with a signiﬁcant increase of OS only in patients
with an ECOG score of 0 to 1 (16.7 vs. 43.3 months,
P ¼ 0.04) (Fig. 2). In patients with an ECOG score of 2 to
3, there was no signiﬁcant difference in OS according to
nephrectomy status, despite a median increase in OS of 4.6
months in the CN group (8.0 vs. 12.6 months, P ¼ 0.8).
Similarly, in patients with good and intermediate MSKCC
risk score, median OS was signiﬁcantly increased among
the nephrectomy group (16.8 vs. 42.4 months, P ¼ 0.02)
(Fig. 3). In poor-risk patients, median OS was similar in
both the groups (5.2 months, P ¼ 0.9).
The number and location of metastases also have a
prognostic effect. OS was signiﬁcantly better in case of isolated
lung metastases (P ¼ 0.04) and when the number of metastases
did not exceed 2 (Po 0.001). Finally, patients treated with
antiangiogenic therapies had better median OS than patients
treated with cytokines did (39.8 vs. 24.1 months, P ¼ 0.03).
Multivariate analysis conﬁrms the positive effect of CN
in the group with good and intermediate MSKCC risk score
and in patients with ECOG score of 0 to 1, regardless of the
metastatic status and the kind of therapy.
4. Discussion
Immunotherapy has been the single systemic treatment
in mRCC for many years. During this era, 2 prospective
randomized studies have demonstrated the survival beneﬁt
Table 1
Patients and tumors characteristics
Median age at diagnosis, y (range) 60.2 (19–91)
Sex, n (%)
Males 252 (71.8)
Females 99 (28.2)
ASA score, n (%)
1 91 (25.9)
2 173 (49.3)
Z3 87 (24.8)
ECOG score before nephrectomy, n (%)
0 128 (36.4)
1 155 (44.2)
2 54 (15.4)
3 14 (4.0)
MSKCC risk group before nephrectomy, n (%)
Good 88 (25.0)
Intermediate 227 (64.7)
Poor 36 (10.3)
Median tumor size, cm (range) 8.5 (3–14)
Histological subtype, n (%)
Clear cell carcinoma 306 (87.2)
Papillary carcinoma 25 (7.1)
Other 20 (5.7)
T category, n (%)
T1 38 (10.8)
T2 43 (12.3)
T3-4 270 (76.9)
Fuhrman grade, n (%)
1 7 (2.0)
2 67 (19.1)
3 177 (50.4)
4 100 (28.5)
Number of metastatic sites at diagnosis, n (%)
1 109 (31.1)
2 126 (35.9)
3 Or more 116 (33.0)
ASA ¼ American Society of Anesthesiologists.
Table 2
Treatment strategies
Cytoreductive nephrectomy, n (%) 298 (84.9)
First-line systemic treatment, n (%)
Sunitinib 137 (39.0)
Sorafenib 65 (18.5)
Temsirolimus 25 (7.1)
Interferon 57 (16.2)
Bevacizumab þ interferon 17 (4.8)
Interferon þ IL2 20 (5.7)
Others 30 (8.7)
IL2 ¼ interleukin-2.
R. Mathieu et al. / Urologic Oncology: Seminars and Original Investigations ] (2015) 1–7 3
of associative CN and interferon-alfa [2,3]. Since a decade,
new drugs have emerged to become standard treatment of
mRCC. Currently, the association of CN with these new
targeted molecules is still recommended based on former
data with immunotherapy. Most of the patients in the
pivotal targeted therapy studies had undergone nephrec-
tomy. However, when considering the safety and efﬁcacy of
presurgical antiangiogenics, some authors are calling into
question the time schedule and even the relevance of such a
procedure. There are 2 phase 3 randomized studies that are
ongoing to partially answer these questions [1]. Immediate
Surgery or Surgery After Sunitinib Malate in Treating
Patients With Metastatic Kidney Cancer (SURTIME;
European Organisation for Research and Treatment of
Cancer [EORTC] 30073) trial is a randomized phase 3 trial
that compares progression-free survival in case of immedi-
ate vs. deferred (after 3 complete cycles of sunitinib) CN in
mRCC. In addition, tumoral tissue and serum are collected
to identify molecular proﬁles predictive of response and
resistance. The Clinical Trial to Assess the Importance of
Nephrectomy (CARMENA) trial is a phase 3 randomized
noninferiority study that evaluates OS with nephrectomy
followed by sunitinib vs. sunitinib alone. Together
CARMENA and SURTIME complement one another, and
both will address the role of CN and the optimal sequence
in the targeted therapy era. Unfortunately, no result is
expected before 2016.
There are retrospective studies that have investigated the
beneﬁt of CN in patients with mRCC treated exclusively
with targeted therapies. Warren et al., in a Canadian
population–based study, identiﬁed CN as an independent
factor of OS improvement in patients with mRCC treated
with tyrosine kinase inhibitors [17]. Choueiri et al. reported
OS of 314 patients with mRCC according to their CN status
[18]. CN was associated with a signiﬁcant increase in OS
(19.8 vs. 9.4 months), even after adjusting for established
prognostic risk factors. More recently, Heng et al. retro-
spectively reported a series of 1,658 patients with mRCC
from the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) and deﬁned a new prognostic
tool using 9 clinical factors to model survival in the era of
targeted therapy. They found that most patients beneﬁted
from tumor removal, except for those with 4 or more IMDC
risk factors [19]. Finally, in a Surveillance, Epidemiology,
and End Results (SEER) database analysis including 7,143
patients with mRCC treated between 2005 and 2009,
among whom 37% underwent CN, CN was signiﬁcantly
associated with improved OS on multivariate analysis [20].
Our results are concordant, as we report that CN performed
before targeted treatments was associated with a signiﬁcant
increase of OS in the entire cohort.
If global beneﬁt of CN has been demonstrated, one
question remains worthwhile: Does every patient with
mRCC take advantage from this surgery? Pivotal studies
in the era of immunotherapy (Southwest Oncology Group
[SWOG] trial 8949 and EORTC trial 30947) only enrolled
patients with PS 0 or 1 [2,3]. Schuch et al. suggested that
surgery in patients who have a poor performance (ECOG 2/
3 patients) may serve a palliative function, but it should be
performed with caution because of the poor outcome of
such patients [21]. Indeed, 42.5% of these patients did not
proceed to receive systemic therapy and presented a median
OS of 6.6 months. Recent studies focusing only on targeted
therapies suggested that CN might not beneﬁt every patient
with mRCC. In the study of Choueiri et al., the beneﬁt was
marginal for patients within a poor prognostic group, as
determined by the MSKCC risk model (P ¼ 0.06) [18].
Heng et al. also concluded to the absence of beneﬁt in
patients with 4 or more risk factors, as determined by the
IMDC [19]. Further retrospective data showed than CN was
Table 3
Comparison of CN and non-CN groups.
CN
(n ¼ 298)
Non-CN
(n ¼ 53)
P value
Median age at diagnosis,
y (range)
59.0 (19–82) 65.5 (28–91) o0.0001a
Median BMI 26.5 26.7 0.86a
Sex, n (%) 0.74b
Males 215 (72.1) 37 (69.8)
Females 83 (27.9) 16 (30.2)
ECOG score before nephrectomy, n (%) 0.01b
0 122 (40.9) 6 (11.3)
1 123 (41.3) 32 (60.4)
2 43 (14.4) 11 (20.8)
3 10 (3.4) 4 (7.5)
MSKCC risk group before nephrectomy, n (%) 0.05b
Good 84 (28.2) 4 (7.5)
Intermediate 186 (62.4) 41 (77.4)
Poor 28 (9.4) 8 (15.1)
Median tumor size, cm (range) 9.3 (4–14) 7 (3–12) 0.01a
Histological subtype, n (%) 0.42b
Clear cell carcinoma 261 (87.6) 45 (84.9)
Papillary carcinoma 22 (7.4) 3 (5.7)
Other 15 (5.0) 5 (9.4)
T category, n (%) 0.39b
T1 35 (11.7) 3 (5.7)
T2 37 (12.4) 6 (11.3)
T3-4 226 (75.9) 44 (83.0)
Fuhrman grade, n (%) 0.17b
1 4 (1.3) 3 (5.7)
2 56 (18.8) 11 (20.8)
3 150 (50.3) 27 (50.9)
4 88 (29.6) 12 (22.6)
Number of metastatic sites (%) 0.13b
1 98 (32.9) 11 (20.8)
2 107 (35.9) 19 (35.8)
3 Or more 93 (31.2) 23 (43.4)
Bold values are signiﬁcant p-value with p o 0.05.
BMI ¼ body mass index.
aStudent t test.
bChi-square test.
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of most beneﬁt in those patients where primary renal tumor
accounts for most of the volume of the disease [22] and
those with the non–clear cell histological subtype [23].
Recently, Ohno et al. suggested that patients with
neutrophil-to-lymphocyte ratio Z4.0 and ECOG-PS Z1
might not beneﬁt from immediate CN after initial
diagnosis [24]. Culp et al. identiﬁed other poor prognostic
factors such as high lactate dehydrogenase level, low
albumin level, symptoms at presentation caused by a
metastatic site, liver metastasis, retroperitoneal adenopathy,
supradiaphragmatic adenopathy, and clinical tumor
classiﬁcationZT3 [25]. Together, these retrospective data
suggest that CN might have a role in some well-selected
individuals [26].
Fig. 1. Overall survival according to the completion of a CN in the entire cohort. (Color version of ﬁgure is available online.)
Fig. 2. Overall survival according to the completion of a CN in the group of patients with ECOG 0-1 score status. (Color version of ﬁgure is available online.)
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In the present study, we demonstrated that only patients
with ECOG score of 0 to 1 or good/intermediate MSKCC
prognostic score had a beneﬁt from CN. On the contrary,
patients with ECOG score of 2 to 3 or poor MSKCC score
did not take advantage from CN. There are several
theoretical reasons why CN might not be beneﬁcial in the
era of targeted therapies. Unlike immune therapy, it is
possible that targeted therapy alone controls the disease,
particularly at the primary tumor site, at the point that
nephrectomy is no more necessary. This might avoid the
morbidity and mortality associated with surgery. In addi-
tion, the delay in starting systemic treatment associated with
the postoperative period might allow further progression of
aggressive disease and, consequently, be counterproductive.
The frequent occurrence of disease progression (approx-
imately 33% by the Response Evaluation Criteria In Solid
Tumors [RECIST] criteria) during a surgery-related treat-
ment break of approximately 3 to 4 weeks in the neo-
adjuvant strategies argues in favor of surgical abstention
[27]. This is particularly suitable for patients with poor
prognostic factors, such as those with an ECOG score of 2
to 3 and in the poor MSKCC score group. Targeted therapy
might be proposed as the ﬁrst-line treatment to these
patients, and CN should be considered only after an
objective response to the systemic treatment. Indeed, in
some cases, delayed nephrectomy could probably be a good
option. Apart from the theoretical advantage of downsizing
of the primary renal tumor, which seems to be quite modest
(2%–6% by the RECIST criteria) and probably does not
facilitate surgery [27–29], the major concern is to quickly
start effective systemic therapy without the delay associated
with planning, performing, and recovering from nephrec-
tomy. Moreover, patients with primary refractory disease
would be accurately identiﬁed and therefore might have an
opportunity to promptly switch to another targeted agent.
Finally, it should be noted that approximately 30% of patients
do not go on to have the planned nephrectomy [27–29].
Our study conﬁrms the results of previous retrospective
series and provides interesting results that need to be taken
into account in the management of mRCC. It suggests that
careful clinical consideration is required before planning
CN in all untreated patients with mRCC, especially
for patients with risk for poor prognosis, as deﬁned by
the MSKCC score and for those with an ECOG score
of 2 or 3. We concede that our study has some limitations
owing to the retrospective and multicentric design. Some
biases are expectable from the variability of systemic
treatments and the time frame between surgery and the
beginning of the adjuvant treatment. Furthermore, there is a
selection bias as patient and tumor characteristics may
affect the surgeon's choice. Indeed, it is noteworthy that
patients in the non-CN group are older and are more likely
to have worse ECOG and MSKCC scores. The debate
regarding the place of CN in the era of targeted therapies is
likely to continue until the ongoing prospective trials report
their ﬁndings [30].
5. Conclusion
Nephrectomy improves OS in patients with mRCC
preferentially treated with targeted therapies. However, this
Fig. 3. Overall survival according to the completion of a CN in the group of patients with good and intermediate MSKCC score status. (Color version of
ﬁgure is available online.)
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effect is limited to patients with good and intermediate
MSKCC prognostic score and to patients with ECOG
performance status of 0 to 1. We consider that CN might
not be proposed to patients with poor prognosis before
systemic treatment and without an objective response to
these drugs. This information may help in patient selection
as we await results from randomized controlled trials.
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